Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

DISKUS vs. ELLIPTA Device Preference Study in Chronic Obstructive Pulmonary Disease (COPD)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT01868009
First received: May 30, 2013
Last updated: January 16, 2014
Last verified: December 2013
  Purpose

Subjects who have not used the ELLIPTA™ inhaler nor the DISKUS™ inhaler in the past 6 months will be screened to participate in the study. Subjects will have an equal chance of being in any of the following two groups (1:1 allocation). One group will be dispensed the ELLIPTA inhaler at Visit 1 to use during the first period (once daily for 5 to9 days), and the DISKUS inhaler at Visit 2 to use during the second period (twice daily for 5 to 9 days). The other group will be dispensed the DISKUS inhaler at Visit 1 to use during the first period (twice daily for 5 to 9 days), and the ELLIPTA inhaler at Visit 2 to use during the second period (once daily for 5 to9 days). At the end of the second period, subjects will complete the study by answering 7 questions to assess their preference of device attributes and dosing regimens between the two inhalers.

The null hypothesis for device preference for a specific attribute is that 50% subjects express a preference in that attribute for ELLIPTA and 50% do NOT express a preference in that attribute for ELLIPTA, i.e., the odds for preferring ELLIPTA to not preferring ELLIPTA is unity.

The null hypothesis for dosing regimen preference is that 50% subjects express a preference of once daily dosing and 50% do not express a preference of once daily dosing (prefer twice daily dosing or have no preference).


Condition Intervention Phase
Pulmonary Disease, Chronic Obstructive
Device: ELLIPTA
Device: DISKUS
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: RLV116669, A Preference Study of Device Attributes Between Two Placebo Dry Powder Inhalers; ELLIPTA and DISKUS, in Adult Subjects With Chronic Obstructive Pulmonary Disease

Resource links provided by NLM:


Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • Number of Participants With the Indicated Device Preference Based on the Size of the Numbers on the Dose Counter [ Time Frame: up to Study Day 26 ] [ Designated as safety issue: No ]
    The number of participants who expressed the indicated device preference (i.e., preference for ELLIPTA inhaler, preference for DISKUS inhaler, and no preference) based on the size of the numbers on the dose counter was summarized by study inhaler use sequence.


Secondary Outcome Measures:
  • Number of Participants With the Indicated Device Preference Based on the Number of Steps Needed to Take the COPD Medication [ Time Frame: up to Study Day 26 ] [ Designated as safety issue: No ]
    The number of participants who expressed the indicated device preference (i.e., preference for ELLIPTA inhaler, preference for DISKUS inhaler, and no preference) based on the number of steps needed to take the COPD medication was summarized by study inhaler use sequence.

  • Number of Participants With the Indicated Device Preference Based on the Size of the Device [ Time Frame: up to Study Day 26 ] [ Designated as safety issue: No ]
    The number of participants who expressed the indicated device preference (i.e., preference for ELLIPTA inhaler, preference for DISKUS inhaler, and no preference) based on the size of the device was summarized by study inhaler use sequence.


Enrollment: 287
Study Start Date: May 2013
Study Completion Date: July 2013
Primary Completion Date: July 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: ELLIPTA Period 1 and DISKUS Period 2 Arm
Subjects will use the ELLIPTA inhaler once daily for 5 to 9 days during the first period followed by the DISKUS inhaler twice daily for 5 to 9 days during the second period.
Device: ELLIPTA
Novel dry powder inhaler (placebo) with 30 doses (2 strips with 30 blisters per strip)
Device: DISKUS
Multidose dry powder inhaler (placebo) containing a foil strip worth 60 blisters (1 strip with 60 blisters per strip)
Experimental: DISKUS Period 1 and ELLIPTA Period 2 Arm
Subjects will use the DISKUS inhaler twice daily for 5 to 9 days during the first period followed by the ELLIPTA inhaler once daily for 5 to 9 days during the second period.
Device: ELLIPTA
Novel dry powder inhaler (placebo) with 30 doses (2 strips with 30 blisters per strip)
Device: DISKUS
Multidose dry powder inhaler (placebo) containing a foil strip worth 60 blisters (1 strip with 60 blisters per strip)

  Eligibility

Ages Eligible for Study:   40 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • 1. Informed consent
  • Subject must give their signed and dated written informed consent to participate.
  • Subject understands and is willing, able, and likely to comply with study procedures and restrictions.
  • Subject must be able to read, comprehend, and record information in English.
  • 2. Age: >=40 years of age at Visit 1
  • 3. Gender: Male or female subjects
  • 4. COPD diagnosis subjects with a clinical history of COPD in accordance with the definition by the American Thoracic Society/European Respiratory Society
  • 5. Severity of disease:
  • Subject with a measured post-albuterol Forced expiratory volume in 1 second (FEV1)/ Forced vital capacity (FVC) ratio of <=0.70 at Visit 1
  • Subjects with a measured post-albuterol FEV1 <=70% of predicted normal values calculated using Third National Health and Nutrition Examination Survey reference equations at Visit 1.
  • Post-bronchodilator spirometry will be performed approximately 10-15 minutes after the subject has self-administered 4 inhalations (i.e., total 400 micrograms) of albuterol via a metered dose inhaler (MDI) with a valved-holding chamber. The FEV1/FVC ratio and FEV1 percent predicted values will be calculated by the investigator site.
  • Documented spirometry measurements that meet this criterion in the last 12 months preceding Visit 1 is acceptable.
  • 6. Tobacco use: current or former smokers
  • Smokers are defined as those who smoke 10 pack-years of cigarette.
  • Note: Pipe and/or cigar use cannot be used to calculate pack-year history.
  • Number of pack years = (number of cigarettes per day/20) x number of years smoked

Exclusion Criteria:

  • 1. Previous experience with the DISKUS inhaler
  • Subjects who used any DISKUS inhaler (e.g., ADVAIR DISKUS, FLOVENT DISKUS®; participated in a clinical study of fluticasone propionate/salmeterol, or any component of them, or placebo) within 6 months (i.e., 180 days) prior to Visit 1.
  • 2. Previous experience with the ELLIPTA inhaler
  • Subjects who used any ELLIPTA inhaler (e.g., participated in a clinical study of FF/VI or GSK573719/GW642444 [umeclidinium/vilanterol], or any component of them, or placebo) within 6 months (i.e., 180 days) prior to Visit 1.
  • 3. Asthma: Subjects with a current diagnosis of asthma.
  • Subjects with a prior history of asthma are eligible if they have a current diagnosis of COPD.
  • 4. Poorly controlled COPD: Subjects with symptoms of poorly controlled COPD such as:
  • Acute worsening of COPD that is managed by the subject with corticosteroids or antibiotics or that requires treatment prescribed by a physician, in the 4 weeks prior to Visit 1.
  • Hospitalization due to acute worsening of COPD within 4 weeks of Visit 1.
  • Use of a total of 8 puffs/day or more of short-acting symptom relief medications such as albuterol and ipratropium for 2 consecutive days or any 3 days within 7 days immediately preceding Visit 1.
  • Changes in COPD symptoms and signs, suggesting worsening COPD health status at Visit 1.
  • 5. Other diseases/abnormalities: Subjects with current evidence of uncontrolled or clinically significant disease.
  • Significant is defined as any disease that, in the opinion of the investigator, would put the safety of the subject at risk through participation, or which would affect the efficacy or safety analysis if the disease/condition exacerbated during the study.
  • Subjects with suspected or evidence of oropharyngeal candidiasis will be excluded from the study.
  • Note: subjects who develop oropharyngeal candidiasis during the study will be treated at the discretion of the investigator.
  • 6. Drug/food allergy: Subjects with a history of hypersensitivity to any of the components of the inhalation powder (e.g., lactose, magnesium stearate). In addition, subjects with a history of severe milk protein allergy that, in the opinion of the investigator, contraindicates the subject's participation will also be excluded.
  • 7. Drug/alcohol abuse: Subjects with a known or suspected alcohol or drug abuse at Visit 1 which in the opinion of the investigator could interfere with the subject's proper completion of the protocol requirement
  • 8. Medication prior to spirometry: Subjects who are medically unable or unwilling to withhold their COPD medications prior to spirometry testing at Visit 1. Subjects, who have documented spirometry measurements that meet the specified Inclusion Criterion in the last 12 months preceding Visit 1, do not have to undergo repeat spirometry at Visit 1.
  • 9. Investigational drug or device: Subjects who participated in an interventional study or used any investigational drug or device within 30 days or 5 half lives, whichever is longer, prior to Visit 1
  • 10. Affiliation with investigator site: Study investigators, sub-investigators, study coordinators, employees of a participating investigator or immediate family members of the aforementioned are excluded from participating in this study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01868009

Locations
United States, Alabama
GSK Investigational Site
Jasper, Alabama, United States, 35501
United States, California
GSK Investigational Site
Riverside, California, United States, 92506
United States, Florida
GSK Investigational Site
Clearwater, Florida, United States, 33765-2616
GSK Investigational Site
Leesburg, Florida, United States, 34748
GSK Investigational Site
Orlando, Florida, United States, 32825
United States, Louisiana
GSK Investigational Site
Lafayette, Louisiana, United States, 70503
United States, North Carolina
GSK Investigational Site
Charlotte, North Carolina, United States, 28207
GSK Investigational Site
Huntersville, North Carolina, United States, 28078
United States, Oregon
GSK Investigational Site
Medford, Oregon, United States, 97504
United States, South Carolina
GSK Investigational Site
Charleston, South Carolina, United States, 29406-7108
GSK Investigational Site
Easley, South Carolina, United States, 29640
GSK Investigational Site
Greenville, South Carolina, United States, 29615
GSK Investigational Site
Seneca, South Carolina, United States, 29678
GSK Investigational Site
Spartanburg, South Carolina, United States, 29303
United States, Texas
GSK Investigational Site
San Antonio, Texas, United States, 78229
United States, Virginia
GSK Investigational Site
Richmond, Virginia, United States, 23225
United States, Washington
GSK Investigational Site
Spokane, Washington, United States, 99204
Sponsors and Collaborators
GlaxoSmithKline
Investigators
Study Director: GSK Clinical Trials GlaxoSmithKline
  More Information

No publications provided

Responsible Party: GlaxoSmithKline
ClinicalTrials.gov Identifier: NCT01868009     History of Changes
Other Study ID Numbers: 116669
Study First Received: May 30, 2013
Results First Received: January 16, 2014
Last Updated: January 16, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by GlaxoSmithKline:
fluticasone furoate
COPD
ELLIPTA
fluticasone propionate
DISKUS
Novel Dry Powder Inhaler (NDPI)
device preference
salmeterol
vilanterol

Additional relevant MeSH terms:
Chronic Disease
Lung Diseases
Lung Diseases, Obstructive
Pulmonary Disease, Chronic Obstructive
Disease Attributes
Pathologic Processes
Respiratory Tract Diseases

ClinicalTrials.gov processed this record on November 25, 2014